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Salk Institute for Biological Studies,
United States
Sujit Kumar Bhutia,
National Institute of Technology
Rourkela, India
Stefano Falone,







This article was submitted to
Cancer Metabolism,
a section of the journal
Frontiers in Oncology
Received: 13 July 2021
Accepted: 07 September 2021
Published: 15 October 2021
Citation:
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Recently, we presented evidence that high mitochondrial ATP production is a new
therapeutic target for cancer treatment. Using ATP as a biomarker, we isolated the
“metabolically fittest” cancer cells from the total cell population. Importantly, ATP-high
cancer cells were phenotypically the most aggressive, with enhanced stem-like
properties, showing multi-drug resistance and an increased capacity for cell migration,
invasion and spontaneous metastasis. In support of these observations, ATP-high cells
demonstrated the up-regulation of both mitochondrial proteins and other protein
biomarkers, specifically associated with stemness and metastasis. Therefore, we
propose that the “energetically fittest” cancer cells would be better able to resist the
selection pressure provided by i) a hostile micro-environment and/or ii) conventional
chemotherapy, allowing them to be naturally-selected for survival, based on their high ATP
content, ultimately driving tumor recurrence and distant metastasis. In accordance with
this energetic hypothesis, ATP-high MDA-MB-231 breast cancer cells showed a dramatic
increase in their ability to metastasize in a pre-clinical model in vivo. Conversely,
metastasis was largely prevented by treatment with an FDA-approved drug
(Bedaquiline), which binds to and inhibits the mitochondrial ATP-synthase, leading to
ATP depletion. Clinically, these new therapeutic approaches could have important
implications for preventing treatment failure and avoiding cancer cell dormancy, by
employing ATP-depletion therapy, to target even the fittest cancer cells.
Keywords: anti-oxidant capacity, ATP, bedaquiline, cancer stem cells (CSCs), dormancy, mitochondria, metastasis,
multi-drug resistanceATP, THE ENERGETIC CURRENCY OF LIFE: HISTORY,
CHEMISTRY AND BIOLOGY
ATP is the vital energetic “currency” of all living things, including micro-organisms (1–11). Viruses
also energetically require sufficient ATP levels, for replication in host cells.
Historically, ATPwas initially discovered in 1929, by Karl Lohmann, a German chemist (Figure 1).
Then, in 1937, Herman Kalckar, from Denmark, showed that ATP synthesis is driven by cellOctober 2021 | Volume 11 | Article 7407201
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scientist, was the first to demonstrate that ATP is used as the
universal chemical energy in cells. However, it wasn’t until 1961,
that an American biochemist, namely Efraim Racker, first isolated
the catalytic F1-subunit of the mitochondrial ATP-synthase. Then,
in 1978, Peter D. Mitchell proposed that the asymmetric
distribution of protons across a topologically enclosed
membrane, plays an important role in mitochondrial ATP
generation. In 1997, the Nobel Prize in Chemistry was jointly
awarded to Paul D. Boyer and John E. Walker, for discovering the
enzymatic mechanism(s), underpinning mitochondrial ATP
synthesis (4–7, 12–16). The mitochondrial ATP-synthase
(Complex V) is an excellent example of a rotary molecular
motor, with an architecture of nanoscale dimensions (4–7).
Chemically, at the molecular level, ATP is a nucleoside
triphosphate, which contains adenine, a ribose sugar, and three
phosphate groups (i.e., adenosine-5’-triphosphate) (1–3).
Enzymatic cleavage of ATP at its terminal phosphate group,
produces two main reaction products, ADP and inorganic
phosphate (Pi), thereby releasing high levels of stored chemical
energy (-30.5 kJ/mole) (1–3). Importantly, free energy released
by the hydrolysis of ATP is also due to the higher stability of the
reaction products, because the reaction is kept away from
equilibrium in living cells. As a consequence, the free energy
released by the hydrolysis of ATP into ADP and Pi, is actually
higher than under standard biochemical conditions.
Biologically, ATP is a required co-factor for a plethora of
biochemical reactions, involved in cellular catabolism, as well as in
anabolic metabolism (8–11). During passive diffusion, small
molecules randomly move via Brownian motion, down the
concentration gradient. Therefore, in living cells, in order to
maintain normal physiology and organismal homeostasis, active
transport is necessary to move molecules directionally and
vectorially, against the concentration gradient, from an area of low
concentration to an area of high concentration. This process of active
transport also involves energy expenditures, in the form of ATP.
Kinases employ ATP for auto- and trans-phosphorylation
reactions, to rapidly transmit information via cellular signalingFrontiers in Oncology | www.frontiersin.org 2cascades, from the plasmamembrane to the cytoplasm, intracellular
organelles and, ultimately, to the nucleus. The enzyme adenylate
cyclase (a family of ten human genes; ADCY1-10) uses ATP as a
precursor, for the generation of the second messenger, cyclic AMP
(3’,5’-cyclic adenosine monophosphate).
ATP is involved in various aspects of protein synthesis. For
example, tRNA-ligases employ ATP hydrolysis for coupling the
20 amino acids to their appropriate tRNAs, for their use by
cellular and mitochondrial ribosomes, during protein synthesis.
During protein translation, molecular chaperones (e.g., HSP70
and HSP90 family members) facilitate proper protein folding, by
acting as enzymatically active ATPases, consuming large
amounts of ATP.
In summary, ATP energetically “fuels”most cellular processes,
including metabolism, active transport, intracellular signaling, as
well as DNA, RNA and protein synthesis. Therefore, it is perhaps
surprising that nutrient fasting and/or caloric restriction (17, 18)
are believed to be one of the best strategies for extending both
healthspan and lifespan, as evidenced by studies using model
organisms (C. elegans, Drosophila and mice), as well as preventing
cancer (19, 20). For example, Resveratrol, a natural anti-aging
phytochemical and caloric restriction mimetic, is a known
inhibitor of the mitochondrial ATP-synthase (21). Moreover,
Resveratrol is also thought to exert its powerful anti-aging
effects, via its sirtuin-dependent mechanisms of action.
More specifically, calorie restriction activates pro-longevity
signaling pathways in model organisms, such as AMPK and the
mitochondrial unfolded protein response (UPRmt), and inhibits
mTOR and insulin/IGF1 signaling (22, 23). These effects may
mechanistically reduce or restrict different processes that
contribute to aging, such as inflammation, loss of proteostasis
and senescence.
Energy for the mitochondrial synthesis of ATP is derived
from the oxidation of NADH and FADH2 by Complexes I-IV of
the mitochondrial electron transport chain (ETC). NADH and
FADH2 are generated mainly from the TCA cycle, but some
NADH is also donated by glycolysis and from the conversion of
pyruvate into acetyl-CoA. However, cytosolic NADH (obtainedFIGURE 1 | A brief history of the discovery of ATP and its energetic function. This timeline highlights the key scientists and the events that contributed to our deeper
understanding the structure, function and molecular machinery responsible for the synthesis of ATP, especially within mitochondrial organelles.October 2021 | Volume 11 | Article 740720
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electron transport chain, but it gives electron equivalents via the
malate-aspartate and/or glycerol shuttles. In contrast, NADPH,
generated by the pentose-phosphate pathway (PPP), is used to
maintain glutathione in a reduced state, providing anti-oxidant
buffering capacity against ROS and oxidative stress.
Because of the central importance of ATP as a “barometer” of
cell metabolism, many luminescent and fluorescent probes have
been developed, to measure and track ATP levels, in response to
various cellular stimuli (24–28). For example, BioTracker ATP-Red
1 is a vital dye that is only fluorescent when bound to ATP, but
does not recognize ADP or other nutrients (29). Morphologically,
BioTracker ATP-Red 1 specifically localizes to mitochondria, as
seen by fluorescence microscopy, and co-localizes with the
mitochondrial probe MitoTracker-Green (29). Therefore,
BioTracker ATP-Red 1 allows for the dynamic detection and
visualization of mitochondrial ATP in living cells and tissues.
As mitochondrial activity is specifically increased in human
tumor cells and metastatic cancer cells in vivo, as measured by
specific functional activity assays, high ATP production may be a
key driving force in promoting tumor progression, therapy-
resistance and, ultimately, in metastatic dissemination (30, 31).
However, more mechanistic studies are needed to experimentally





In our recent studies, we took advantage of a vital fluorescent dye
that allows one to measure ATP levels in living cells, namely
BioTracker ATP-Red 1 (32, 33). More specifically, we coupled
BioTracker ATP-Red 1 staining with a bioenergetic fractionation
scheme, in which the total cell population was subjected to flow
cytometry, to isolate the ATP-high and ATP-low sub-
populations of MCF7 cells, an ER(+) human breast cancer cell
line. This metabolic fractionation approach allowed us to isolate
the most “energetic” cancer cells within the total cell population.
One possibility is that increased mitochondrial metabolism and/
or ROS production may contribute to this phenotype, via
mitochondrial retrograde signalling (34, 35). Therefore, we
proposed that the ATP-high cancer cell population should be
targeted for eradication via ATP-depletion therapy (36–40).
ATP-depletion therapy would be expected to result in rapid
energy-depletion, especially in highly aggressive cancer cells,
thereby halting their propagation, by inducing autophagy,
apoptosis and/or necrosis.
In a parallel line of research, we have previously identified
>20 mitochondrially-targeted therapeutics that could be used
to effectively achieve ATP-depletion therapy (Figure 2).
These potential therapeutics include: FDA-approved drugs
(Doxycycline, Tigecycline, Azithromycin, Pyrvinium pamoate,
Atovaquone, Bedaquiline, Niclosamide, Irinotecan); naturalFrontiers in Oncology | www.frontiersin.org 3products/nutraceuticals (Actinonin, CAPE, Berberine, Brutieridin,
Melitidin); and experimental compounds [Oligomycin, AR-C155858,
Mitoriboscins, Mitoketoscins, Mitoflavoscins, TPP derivatives
(including Dodecyl-TPP and 2-Butene-1,4-bis-TPP)] (41–47).
A triple-combination of two antibiotics together with Vitamin C
(Doxycycline, Azithromycin and Ascorbic acid) was found to
be particularly potent for targeting mitochondria, inducing
ATP-depletion and inhibiting CSC propagation (48), at sub-
antimicrobial levels.
As many of these are repurposed FDA-approved antibiotics,
with excellent safety profiles, Phase II clinical trials are
warranted. For example, a Phase II clinical pilot study of
Doxycycline (49) has already shown that this >50-year-old
antibiotic is indeed effective in metabolically targeting the CSC
population in early breast cancer patients, as demonstrated using
CD44 and ALDH1 as specific CSC markers (49). Mitochondrial
ATP-depletion therapy is expected to functionally mimic fasting
and/or caloric restriction, thereby more effectively starving CSCs
to death. This has important implications for cancer prevention
(50–52) and for potentially extending human lifespan during
aging (53).
Recently, we also demonstrated that treatment with a panel of
mitochondrially-targeted therapeutics, which potently inhibit
mitochondrial protein translation or OXPHOS, could block
tumor cell metastasis, using an in vivo pre-clinical model (54–
56). These results indicated that ATP levels are functionally
critical for the processes fueling aggressive tumor cell behaviors
and spontaneous metastasis.
In further support of our hypothesis, other mitochondrial
inhibitors are known to have promising anti-cancer effects,
including IACS-010759, Gboxin, b1-blockers, Nebivolol, and
Benzethonium (57–60).SURVIVAL OF THE “FITTEST”: ATP-HIGH
CANCER CELLS SHOW A MULTI-DRUG
RESISTANT PHENOTYPE, WITH
ENHANCED ANTI-OXIDANT CAPACITY
Previous studies have shown that high anti-oxidant capacity, due
to increased levels of reduced glutathione, elevated NADPH, and
activated NRF2 signaling, significantly contributes to the onset of
multi-drug resistance (61–67). Consistent with this hypothesis,
recently we directly showed that ATP-high MCF7 cells have an
increased anti-oxidant capacity, with elevated levels of reduced
glutathione, and are intrinsically resistant to four different classes
of drugs (Tamoxifen, Palbociclib, Doxycycline and DPI) (33).
Therefore, the existence of the ATP-high CSC phenotype may
help to mechanistically explain the pathogenesis of multi-drug
resistance, during cancer therapy (Figure 3). In this context,
current cancer therapy may allow only the metabolically “fittest”
cancer cells to survive.
More specifically, as we have shown that the ATP-high
phenotype is indeed transient, consistent with a “stemness”
phenotype, external selection pressure created by a hostile
environment, such as chemo-therapy, may further stabilize thisOctober 2021 | Volume 11 | Article 740720
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required for the survival of only the “fittest” cancer cells, allowing
their propagation, under these harsh conditions.
Our recent findings with ATP-high MCF7 cells are also
consistent with several other studies that establish a direct
causal relationship between mitochondrial “power” and
Tamoxifen-resistance. For example, MCF7-TAMR cells that
were generated via chronic exposure to increasing concentrations
of Tamoxifen, resulting in Tamoxifen-resistance, showed elevatedFrontiers in Oncology | www.frontiersin.org 4levels of mitochondrial OXPHOS and ATP production (66).
In MCF7-TAMR cells, acquired Tamoxifen-resistance was due to
the over-expression of two key anti-oxidant proteins (NQO1 and
GCLC) and their positive metabolic effects on mitochondrial
metabolism, as revealed by unbiased proteomics analysis (66). In
addition, recombinant over-expression of either NQO1 or GCLC
in MCF7 cells autonomously conferred an ~2-fold increase in
mitochondrial ATP-production and Tamoxifen-resistance (66).
Moreover, recombinant over-expression of a somatic mutationFIGURE 2 | Mitochondrial complexes I to IV can be safely targeted with FDA-approved drugs. This diagram illustrates that ATP-depletion can be induced in
cancer cells by employing FDA-approved mitochondrial inhibitors that either i) block OXPHOS directly or ii) block OXPHOS indirectly, by halting mitochondrial
protein translation. Inhibition of mitochondrial ATP production is a manageable side-effect that can re-purposed as a therapeutic effect to target and halt the
propagation of CSCs. Inhibitors of mitochondrial protein translation (Doxycycline, Tigecycline and Azithromycin) prevent the production of the 13 proteins
encoded by mitochondrial DNA (mt-DNA), including key subunits of complex I, III, and IV, as well as complex V (MT-ATP6, MT-ATP8) and Humanin (MT-RNR2).October 2021 | Volume 11 | Article 740720
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associated with acquired Tamoxifen-resistance in breast cancer
patients, genetically conferred elevated mitochondrial biogenesis,
OXPHOS and high ATP production (68). The proteomic profiles
of MCF7-TAMR cells and MCF7-ESR1(Y537S) cells also showed
considerable overlap in the biological processes that were
functionally activated (68). Finally, 60 gene products
functionally-associated with mitochondrial ATP production,
were predictive of Tamoxifen-resistance in ER(+)/Luminal A
breast cancer patients (69). These predictive biomarkers included
18 different mitochondrial ribosomal proteins (MRPs) and
>20 distinct components of the mitochondrial OXPHOS
complexes. Therefore, our recent results showing that “naïve”
ATP-high MCF7 cells are intrinsically Tamoxifen-resistant,
without any prior exposure to the drug, have important clinical
implications for optimizing the effectiveness of hormonal breast
cancer therapy.
Interestingly, it has been previously reported that treatment
with conventional chemotherapeutic regimens, actually increases
the number of CSCs, while selectively killing “bulk” cancer cells
(70), but no metabolic hypotheses have been proposed to explainFrontiers in Oncology | www.frontiersin.org 5this phenomenon. In accordance with our “ATP-based
hypothesis”, Chan and colleagues (from Genentech, Inc.)
examined the effects of gemcitabine and etoposide on the total
cancer cell population (71). Remarkably, they observed that after
treatment with gemcitabine and etoposide, the population of
surviving cells showed an increase in ATP content, elevated
mitochondrial mass, with more mitochondrial respiration (71).
However, they did not propose a mechanistic explanation for
these observations, nor did they consider the CSC population.
Instead, they simply concluded that measuring ATP is not a good
read-out to assess the effectiveness of chemo-therapeutic agents.
Given our current findings with ATP-high cells, an alternate
interpretation of their results is that gemcitabine and etoposide
selectively killed the ATP-low sub-population of cancer cells,
thereby enriching for the “energetic” ATP-high sub-population,
which are more stem-like and drug-resistant. Therefore, new
drug discovery should be initiated to help eradicate the ATP-
high sub-population of cancer cells.
Higher intracellular ATP levels have also been suggested to
account for acquired drug-resistance to oxaliplatin and cisplatin,
in a variety of chronically-treated colon and ovarian cancer cellFIGURE 3 | High ATP levels are a major driver of aggressive cancer cell phenotypes. ATP-high cancer cells show increases in many aggressive properties or
behaviors, including cell proliferation, stemness, anchorage-independence, migration, invasion, metastasis, anti-oxidant capacity and drug-resistance. In contrast,
more “dormant” CSCs show low ATP levels. High mitochondrial ATP production may be related to increases in mitochondrial mass in ATP-high cancer cells.October 2021 | Volume 11 | Article 740720
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mechanisms have been proposed, including increased glycolysis
and/or mitochondrial metabolism (72, 73). However, in these
previous studies, ATP levels were measured only after
chronically selecting for the drug resistant cell population.
Therefore, a direct cause-effect relationship between ATP
production and drug resistance could not be established.
Taken together, these findings are internally consistent with
the idea that the high selection pressure afforded by these
conventional chemotherapeutic agents ultimately drives the
natural-selection and survival of only the “energetically fittest”
cancer cells, namely the ATP-high sub-population. Therefore, in
the future, new drug therapies must be implemented, to target
and eradicate the ATP-high population of cancer cells, to prevent
the accumulation of an aggressive, metastatic sub-population of
tumor cells.TUMOR DORMANCY AND
MULTI-DRUG RESISTANCE: ARE THEY
INTER-RELATED?
According to the conventional view of tumor dormancy,
dormant cancer cells undergo slower rates of cell proliferation
and/or cell cycle arrest (quiescence), to avoid therapy-induced
cell death, leading to multi-drug resistance (67, 74). Surprisingly,
recently we observed just the opposite phenomenon. ATP-low
MCF7 cells were less proliferative, with >87% of the cells in the
G0/G1 phase of the cell cycle, but were actually more sensitive to
4 different classes of drugs, using the 3D-mammosphere assay as
a readout (33). Conversely, ATP-high MCF7 cells were
significantly more proliferative, with >38% of the cells in either
S-phase or G2/M, showing a clear multi-drug resistance
phenotype. Therefore, high levels of mitochondrial ATP appear
to be a key driver of both elevated cell proliferation and drug-
resistance, as they represent the energetically “fittest” population
of cancer cells (Figure 3).DEFINING A METASTASIS GENE
SIGNATURE, USING BIOINFORMATICS:
VALIDATING THE IMPORTANCE OF
ATP5F1C, USING SEVERAL
INDEPENDENT DATA SETS AND
MDA-MB-231 CELLS
To interrogate the possible role of mitochondrial ATP production
in the process ofmetastasis, we also used a bioinformatics approach
(33).Briefly,we intersecteda series of publicly-availableGEObreast
cancerDataSets and defined ametastasis-associated gene-signature
consisting of five ATP-related genes, namely ATP5F1C, UQCRB,
COX20, NDUFA2, andABCA2 (Figure 4). Notably, twomembers
of the signature, ATP5F1C and UQCRB, are both known markers
of maximal oxygen uptake (V02max) in mitochondrial-rich human
skeletal muscle fibers (75).Frontiers in Oncology | www.frontiersin.org 6Interestingly, ATP5F1C appeared to be the most relevant
member of this metastasis signature, as it is directly connected to
ATP-synthesis (76). ATP5F1C is the gamma subunit of the
mitochondrial ATP synthase (Complex V) and is directly
involved in converting physical energy (torque) into chemical
energy (ATP) (33, 76).
To further validate and confirm the relevance of ATP5F1C,
we next used a third completely independent database, namely
the “The Metastatic Breast Cancer Project”, which includes
mRNA expression profiling data (RNA Seq V2 RSEM) from
the RNA-sequencing of metastatic breast cancer samples, derived
from N=146 patients (Figure 4). In this context, the mRNA
expression of ATP5F1C was positively correlated with the co-
expression of numerous breast CSC markers, circulating tumor
cell (CTC) markers, metastasis markers, cell cycle regulatory
proteins, and other mitochondrial-related genes, as well as three
other members of the metastasis gene signature (UQCRB,
COX20, NDUFA2). Independently, using Kaplan-Meier (K-M)
analysis, high levels of ATP5F1C mRNA transcripts specifically
predicted poor clinical outcomes in breast, ovarian and lung
cancer patients (33).
To provide functional validation, we next used MDA-MB-231
cells as a metastatic model for triple-negative breast cancer.
Interestingly, ATP-high MDA-MB-231 cells over-expressed
ATP5F1C, as well as other members of mitochondrial complexes I-
V and CTC markers (Ep-CAM1 and VCAM1), all relative to ATP-
lowMDA-MB-231 cells. ATP-highMDA-MB-231 cells also showed
notable increases in ATP-production, proliferation, anchorage-
independent growth, cell migration, invasion and spontaneous
metastasis (Figure 3). Conversely, inducible knock-down of
ATP5F1C in MDA-MB-231 cells was indeed sufficient to inhibit
ATP-production, anchorage-independentgrowthandcellmigration.
Moreover, ATP-high sub-populations of MDA-MB-231 and
MCF7 cells both showed features of multi-drug resistance,
consistent with a more aggressive cancer cell phenotype.
Therefore, ATP5F1C may be an attractive target for new drug
development and metastasis prevention.REPURPOSING BEDAQUILINE TO
PREVENT ATP PRODUCTION, CANCER
CELL MOTILITY, AND SPONTANEOUS
METASTASIS IN VIVO: TARGETED DOWN-
REGULATION OF ATP5F1C
Are there any existing FDA-approved inhibitors of the
mitochondrial ATP-synthase that could be repurposed to target
and prevent cancer metastasis? This would certainly accelerate
future clinical trials, as FDA-approved drugs can re-enter Phase II
trials, for another clinical indication, completely skipping Phase I,
which is specifically focused on safety and toxicity.
Bedaquiline is a clinically-approved drug, that is usually used for
anti-tuberculosis therapy, especially in the context of drug-resistant
TBstrains.More specifically, Bedaquilinewas originallydesigned to
target and block the activity of the ATP-synthase in mycobacteria.
Perhaps surprisingly, recent studies have also demonstrated thatOctober 2021 | Volume 11 | Article 740720
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mitochondrial ATP-synthase, as an off-target side effect (77). In
addition, using cryo-EMasa tool for structural studies, investigators
have localized the binding site of Bedaquiline to the integral
membrane subunit (F0), using the yeast mitochondrial ATP-
synthase. Since the soluble F1 subunit is physically tethered to the
membrane-bound F0 subunit via the gamma-subunit (ATP5F1C)
(76), we hypothesized that ATP5F1C might be mis-folded and
degraded in the presence of Bedaquiline. This would effectively
disrupt ATP synthesis, as ATP5F1C functions as the rotating
central stalk that helps convert torque into chemical energy, in
the form of ATP (Figure 5).
Interestingly, we observed that ATP5F1C was effectively down-
regulated after Bedaquiline treatment in MDA-MB-231 cells,
resulting in significant reductions in ATP production, stemness,
anchorage-independent growth and cell migration (33).
Bedaquiline-induced cell death in MDA-MB-231 cells was
related to the onset of autophagy and necrosis, but apoptosis was
not observed. Remarkably, the expression of ATP5F1C and ATP-
production, as well as cell growth, remained unaffected after
Bedaquiline treatment in MCF-10A cells, a non-tumor-producingFrontiers in Oncology | www.frontiersin.org 7human breast epithelial cell line. Therefore, the effects of
Bedaquiline appeared to be restricted to cancer cells. Similarly,
Bedaquiline inhibitedATP-production inMCF7breast cancer cells,
butnot inhTERT-BJ1cells, a normalhumanfibroblast cell line (44).
As a result of these findings, we tested the efficacy of
Bedaquiline in a pre-clinical xenograft model, namely the
CAM assay, which uses chicken eggs as the host for measuring
tumor growth, spontaneous metastasis and drug toxicity (33).
Our results demonstrated that Bedaquiline had no effect on
MDA-MB-231 tumor growth, but effectively prevented
spontaneous metastasis, by nearly 85%, at a concentration that
did not show any significant chicken embryo toxicity (Figure 5).
As a consequence, we suggest that Bedaquiline could be re-
purposed to prevent spontaneous metastasis, by driving ATP-
depletion via its targeting of the ATP5F1C subunit, within the
mitochondrial ATP-synthase multi-subunit complex. As such,
clinical trials may be warranted.
We speculate that Bedaquiline, by mechanistically targeting
the gamma-subunit of the ATP synthase, may promote
dissociation of the F1-domain of the enzyme and thereby
promote the opening of the transition pore (78–80). RecentFIGURE 4 | Using several independent data sets to identify ATP5F1C as a key biomarker and therapeutic target for metastasis prevention. In order to define an
ATP-related metastasis gene signature we first intersected two GEO DataSets focused on breast cancer metastasis (namely, GSE2034 and GSE59000),
resulting in 5 common genes. The positive co-expression of ATP5F1C, with 3 other members of this gene signature (UQCRB, COX20, NDUFA2), was indeed
confirmed by analyzing data from The Metastatic Breast Cancer Project (Provisional, February 2020; DataSet 3; https://mbcproject.org). Finally, 2 of these 4
gene transcripts (ATP5F1C and UQCRB) were independently found to be specifically-associated with i) maximal oxygen uptake (VO2max) and ii) a higher
percentage of mitochondrial-rich (type 1) fibers, in human skeletal muscle (DataSets 4/5), especially during exercise training. Therefore, ATP5F1C and UQCRB
are likely to be key biomarkers of high OXPHOS and high mitochondrial ATP production in cancer cells. Modified from Reference 33 and reproduced with
permission, under a Creative Commons License.October 2021 | Volume 11 | Article 740720
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the permeability transition pore (PTP) (78, 79). Prolonged
opening of the PTP permeabilizes the inner mitochondrial
membrane to small solutes and constitutes the point of no
return in the execution of cell death.
Finally, the mitochondrial ATP-synthase is indeed subjected to
numerous post-translationalmodifications (such as phosphorylation,
as well as acetylation and succinylation on key lysine residues). Of
course, this can potentially affect its level of enzymatic activity,
and could perhaps explain the phenotypic differences between
ATP-high and ATP-low cancer cells. Regarding Bedaquiline, this
FDA-approved drug is known to bind directly to the ATP-
synthase, but it is not known if Bedaquiline affects the status of
these post-translational modifications.CONCLUSIONS
In conclusion, we recently employed bioenergetic cell
“stratification” using an ATP-based biomarker to isolate the
metabolically “fittest” cancer cells. Using this novel approach, weFrontiers in Oncology | www.frontiersin.org 8obtained the first evidence that high levels of mitochondrial ATP
are a primary determinant of aggressive cancer cell behavior(s),
including spontaneous metastasis. These findings have
important therapeutic implications for preventing treatment
failure in cancer patients, which remains an urgent unmet
clinical need.
For example, energetic cell profiling, using ATP as a
biomarker, can provide a reliable source of ATP-high CSCs i)
for establishing “living” tumor bio-banks and ii) for conducting
small-molecule library screening, targeting drug resistance. This
new conceptual framework will allow novel strategies to be
developed to therapeutically target and eradicate even the
energetically “fittest” CSCs, to ultimately abrogate drug
resistance and metastasis.
In direct support of these observations, Kalluri and colleagues
(81) observed that shRNA-mediated down-regulation of the key
mitochondrial transcription factor, namely PGC-1a, significantly
inhibited lung metastasis, in several independent cell lines
(MDA-MB-231, 4T1 and B16F10 melanoma cells), but had
little or no effect on tumor growth. These observations are
consistent with the idea that targeted down-regulation ofFIGURE 5 | Targeting the human mitochondrial ATP synthase with Bedaquiline, an FDA-approved drug, prevents spontaneous metastasis. Mitochondrial ATP-
synthase is a nano-scale rotary molecular motor that uses the transport of hydrogen ions to generate physical energy in the form of torque that is then converted into
chemical energy in the form of ATP. Rotation of the gamma-subunit (ATP5F1C) helps to convert physical energy into chemical energy. Note that Bedaquiline
treatment induces the degradation or down-regulation of the gamma-subunit (ATP5F1C), resulting in ATP-depletion and the prevention of metastasis.October 2021 | Volume 11 | Article 740720
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population (31, 32, 82), although the authors did not directly
address the issue of the CSC phenotype.
Similarly, high expression levels of the ATP synthase inhibitory
factor 1 (IF1), which inhibits the activity of the mitochondrial ATP
synthase, predicts a better outcome for breast cancer patients,
especially in the case of triple-negative breast cancer (83, 84).
Moreover, IF1 over-expression reduces the production of ATP in
mitochondria and decreases the proliferation and invasiveness of
triple-negative breast cancer cells (84).
Finally, mitochondrial DNA-encoded (mt-DNA) cytochrome c
oxidase II (MT-CO2) is an essential component of mitochondrial
complex IV of the respiratory chain; without MT-CO2, electron
transport and mitochondrial ATP production cannot proceed.
Recently, Lebok and colleagues (85) showed that high levels of
MT-CO2 protein expression in a cohort of approximately 2,000
breast cancer patients, from Germany and Switzerland, were
clinically associated with advanced tumor stage, higher tumor
grade, lymph nodal metastasis and shorter overall survival (P <
0.0001 each). Moreover, at the molecular level, high MT-CO2
protein expression was associated with elevated Ki67 (a marker of
cell proliferation), the genetic amplification of several oncogenes
(HER2, MYC, CCND1 and MDM2), the deletion of PTEN (a
known tumor suppressor) and the down-regulation of estrogen
receptor (ER-alpha) expression (85). As MT-CO2 is a well-
established surrogate marker of mitochondrial DNA content and
mitochondrial protein translation, these results clinically establish
that high mitochondrial content (85) is a functional biomarker of
aggressive tumor progression and metastasis, as well as poor
prognosis and reduced overall survival. In further support of
these clinical observations, MT-CO2 is over-expressed by >20-
fold in an hTERT-enriched sub-population of breast cancer stem
cells (86). Pharmacologically,MT-CO2 is effectively targeted by the
FDA-approved antibiotic Doxycycline (87), which behaves as an
inhibitor of mitochondrial protein translation and prevents ATPFrontiers in Oncology | www.frontiersin.org 9production (87), ultimately blocking metastasis in preclinical
models (54). Therefore, Doxycycline may also provide a
therapeutic solution for inhibiting MT-CO2 in breast cancer
patients, to help prevent disease progression.
Taken together, these multiple lines of experimental evidence
are all consistent with the idea that mitochondrial ATP-depletion
therapy should be pursued as a viable means to provide
metastasis prophylaxis in cancer patients.AUTHOR CONTRIBUTIONS
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Copyright © 2021 Fiorillo, Ózsvaŕi, Sotgia and Lisanti. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.October 2021 | Volume 11 | Article 740720
